Cybrexa: pH-based tumor targeting
How Cybrexa’s delivery platform could reduce PARP inhibitor toxicity in cancer
Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors.
Cybrexa uses its alphalex technology to conjugate a cancer agent to a pH-sensitive peptide via an undisclosed linker. The peptide forms a transmembrane α-helix only